Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 17/20 | 0.47 |
| ▸ | FAP | Q12884 | 4/20 | 0.47 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6357606 | 0.85 | DPP4 (0.59) | DPP4FAPCHRM1 | |
| SCHEMBL3915949 | 0.83 | DPP4 (0.70) | DPP4FAPCHRM1ALDH1A1 | |
| SCHEMBL13936235 | 0.82 | DPP4 (0.42) | DPP4FAPCHRM1 | |
| SCHEMBL3919282 | 0.81 | DPP4 (0.64) | DPP4FAPCHRM1ALDH1A1SMN1; SMN2 | |
| SCHEMBL3926824 | 0.81 | DPP4 (0.67) | DPP4FAPCHRM1 | |
| SCHEMBL4487837 | 0.80 | KMT2A (0.60) | DPP4ALDH1A1SMN1; SMN2RAB9ALMNA | |
| SCHEMBL3968398 | 0.80 | DPP4 (0.74) | DPP4FAPCHRM1 | |
| SCHEMBL3968402 | 0.80 | DPP4 (0.74) | DPP4FAPCHRM1 | |
| SCHEMBL3918944 | 0.79 | DPP4 (0.54) | DPP4FAPCHRM1 | |
| SCHEMBL4482398 | 0.79 | DPP4 (0.71) | DPP4FAPALDH1A1SMN1; SMN2HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7550455-B2 | 8-(piperazin-1yl)- and 8-([1,4]diazepan-1yl)-xanthines, the preparation thereof and their use as pharmaceutical composition | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-06-23 | — | — | US | disclosed |